Some of the deals may be trendsetters not only in their own domain but also in the induatry as well. Looking ahead one can say in the wake of drug failures happenings across the belt of the pharmaceutical industry, the regulator’s cautionary approach in analysing drug efficacy, the investors’ not willing to shell out their precious wealth in a hurry, the patient’s not willing to enroll in clinical trials till they are promised shield/cover from adverse events and finally the governments’ not willing to reimiburse a new drug till it is completely efficacious, it becomes neccesary for the companies in clinical development adopt a partnering/deal approach.
Recent examples of the deals taking place today between Pharma, Biotechs and CRO’s across the globe are as follows:
Merck Teams Up With Parexel in Move into Biosimilars
Merck & Co. (MRK) formed an alliance with a contract research provider as part of its push to sell new versions of big-selling biotechnology drugs. Parexel International Corp. (PRXL) will provide clinical development services for so-called “biosimilar” candidates to Merck’s BioVentures unit. Biosimilars are intended to be close copies of biologics, which are large-molecule drugs derived from living cells, as opposed to traditional chemical-based, small-molecule drugs. A Merck BioVentures unit will be formed within Parexel; financial terms of the deal weren’t disclosed.
Sanofi-aventis enters into Two Research & Development Collaborations with the University of California, San Francisco
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and the University of California, San Francisco (UCSF) announced today that they have formed two research and development collaborations that join together leaders from academia and industry to more rapidly advance groundbreaking innovation from the lab to the patient. The first collaboration promotes innovative research in pharmacological science and in multiple therapeutic areas, such as oncology, aging, diabetes and inflammation. The second collaboration is an oncology partnership that will focus on project-based collaboration to accelerate the progression of research through the clinical proof of concept stage. Sanofi-aventis will be the first industry partner for UCSF’s Program for Breakthrough Biomedical Research (PBBR).
PPD, Inc. announced it has established a joint venture with Taijitu Biologics Limited (TBL) in the area of the discovery of novel biotherapeutics. The joint venture, named BioDuro Biologics, expands PPD’s capability to deliver unique, highly differentiated drug discovery services for biopharmaceutical companies across the globe.
PPD and TBL formed BioDuro Biologics to develop and commercialize an innovative technology platform for the discovery of first- and best-in-class monoclonal antibody therapies in collaboration with MAB Discovery GmbH in Munich, Germany. The joint venture will provide drug discovery services based on this technology platform to global biopharmaceutical companies, enabling them to discover best-in-class monoclonal antibodies against both novel and validated targets